Last reviewed · How we verify
Placebo of Risperidone ISM — Competitive Intelligence Brief
phase 3
Psychiatry
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo of Risperidone ISM (Placebo of Risperidone ISM) — Rovi Pharmaceuticals Laboratories. This is a placebo control formulation used in clinical trials to compare against the active Risperidone ISM (intramuscular sustained-release) antipsychotic.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo of Risperidone ISM TARGET | Placebo of Risperidone ISM | Rovi Pharmaceuticals Laboratories | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo of Risperidone ISM CI watch — RSS
- Placebo of Risperidone ISM CI watch — Atom
- Placebo of Risperidone ISM CI watch — JSON
- Placebo of Risperidone ISM alone — RSS
Cite this brief
Drug Landscape (2026). Placebo of Risperidone ISM — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-of-risperidone-ism. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab